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Abstract The thiol protease bromelain has been shown to remove T-cell CD44 molecules from lymphocytes and to affect T-cell activation. We 
investigated the effect of a highly purified bromelain protease F9 (F9) on the adhesion of peripheral blood lymphocytes (PBL) to human umbilical 
vein endothelial cells (HUVEC). Preincubation of the lymphocytes with F9 reduced the adherence to about 20% of unstimulated and to about 30% 
of phorboldibutyrate (P(Bu)2) stimulated lymphocytes. Using flow cytometry, both crude bromelain and protease F9 reduced the expression of CD44, 
but not of LFA-1, on PBL. F9 was about 10 times more active than crude bromelain; at 2.5/lg/ml of F9 about 97% inhibition of CD44 expression 
was found. A mAb against CD44 was tested and found to block the F9-induced ecrease in PBL-binding to HUVEC. The results indicate that F9 
selectively decreases the CD44 mediated binding of PBL to HUVEC. 
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1. Introduction 
The interaction of lymphocytes with either specialized endo- 
thelium in lymphoid organs or activated endothelial cells re- 
presents the first critical step in lymphocyte migration into 
lymphoid tissues or into inflammatory sites. Adhesion of lym- 
phocytes to endothelial cells involves multiple receptor ligand 
interactions, e.g. LFA-1 to ICAM-1 and ICAM-2, CD44 and 
VLA-4 to VCAM-1 [1]. Recent studies have demonstrated that 
CD44 is the primary receptor for hyaluronate [2]. In man, the 
CD44 molecule (the putative homing receptor) has been of 
interest because of its multiple proinflammatory functions and 
regulation of the function of  other adhesion molecules [3]. The 
involvement of CD44 in lymphocytes binding to activated en- 
dothelial cells was proven by the use of CD44 specific monoclo- 
nal antibodies, which block lymphocyte binding [4]. On the 
other hand CD44 binding to cultured endothelial cells was 
blocked by the treatment of these cells with hyaluronidase [2]. 
However, other studies have shown that the role of CD44 in 
lymphocyte binding may be indirect, suggesting that CD44 
binds to additional igands [5]. CD44 molecules may be also 
involved in T-lymphocyte activation. On T-cells, ligand binding 
to the CD44 molecule promotes T-cell activation, interleukin-2 
release and T-cell adhesion to monocytes [6]. 
Treatment of T-lymphocytes with the thiol protease bro- 
melain has been shown to remove surface CD44 as well as other 
surface molecules, whereas leaving CD2, CD3 and CD28 mol- 
ecules intact. This effect is associated with enhanced CD2 me- 
diated T-cell activation and T-cell binding to monocytes [7]. 
However, since bromelain is a mixture of different basic and 
acidic proteases as well as undefined ifferent components (T. 
Harrach et al., submitted for publication), the relationship of 
these findings to well characterized bromelain derived pro- 
teases remains to be determined. 
In order to test the role of CD44 molecules on lymphocyte 
adherence, we investigated the effect of  a highly purified basic 
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bromelain protease F9, with defined proteolytic activity, on 
human peripheral blood lymphocytes (PBL) with respect to 
their ability to adhere to human umbilical vein endothelial cells 
(HUVEC). In addition, the protease ffects on CD44 and LAF-  
1 expression on lymphocytes were analyzed using flow cytom- 
etry. Our results indicate that F9 selectively decreases the CD44 
mediated binding of PBL to HUVEC.  
2. Materials and methods 
2.1. Preparation of lymphocytes 
Lymphocytes (PBL) were isolated by a single-step method. About 
20-40 ml of freshly isolated blood were obtained from healthy volun- 
teers, anticoagulated with preservative free heparin (10 U/ml final con- 
centration, from Sigma) and layered onto Polymorphoprep (Nycomed 
Pharma). After centrifugation (400 × g, 30 min) at 37°C the lympho- 
cytes were harvested from the first leukocyte band and washed two 
times with warm PBS. Non-adherent cells (PBL) were obtained after 
adherence of peripheral blood mononuclear cells (PBMC) to plastic 
culture dishes for 60 min at 37°C, yielding > 97% viability by Trypan 
blue exclusion. 
2.2. Endothelial cell cultures 
Umbilical cords were obtained from recent deliveries. Endothelial 
cells (EC) were isolated from individual human umbilical cord veins by 
collagenase (from Sigma) digestion, using a modified method by Jaffe 
et al. [8]. EC were suspended in culture medium that contained RPMI 
1640 medium, 20% fetal calf serum (FCS), 200 U/ml penicillin and 
streptomycin (Boehringer Mannheim, Germany), 5 U/ml heparin and 
50 pg/ml endothelial cell growth supplement (ECGS, Boehringer 
Mannheim, Germany). After an overnight incubation at 37°C, 5% CO2, 
the EC cultures were washed and cultured to confluency in the medium 
described above. EC of the first to second passage were used in these 
studies. 
2.3. BCECF-AM labeling of lymphocytes 
BCECF-AM (acetoxymethyl-ester of 2',7'-bicarboxyethyl-5,6-car- 
boxy-fluorescein from Molecular Probes, USA) was dissolved in 
DMSO and kept at -20°C in the dark. The stock solution was diluted 
with RPMI 1640 to give a 2.3 mM solution and used for labelling at 
1:600 dilution. Leukocyte cell suspensions were washed in RPMI 1640 
and resuspended in RPMI 1640 to a concentration f 106 cells/ml. Cells 
were labeled with BCECF-AM for 30 min, at 37°C, 5% CO2 and 
-> 100% relative humidity. After labeling leukocytes were washed twice 
with RPMI 1640 and resuspended in RPMI 1640 + 10% FCS. 
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2.4. Bromelain protease F9 treatment of PBL 
Bromelain F9 was prepared from crude stem bromelain using a two 
step cation-excange chromatography; its proteolytic activity was deter- 
mined using Pyr-Phe-Leu-pNA as substrate (T. Harrach et al., submit- 
ted for publication). Unless stated otherwise batches of F9 with prote- 
olytic activity of 1.91 U/mg were used. 
Peripheral blood lymphocytes (PBL) at a concentration of 5 × 106 
cells/ml were preincubated in the abcence or presence of crude bro- 
melain or F9 at different concentrations for60 min, 37°C, 5% CO2 and 
washed two times with warm PBS. Inactivation of F9 was performed 
with iodoacetamide as described (T. Harrach et al., submitted for pub- 
lication). The cells were resuspended in RPMI 1640 and labeled with 
BCECF-AM, washed and resuspended in RPMI 1640 + 10% FCS. 
2.5. Adhesion assay 
EC at confluence were removed from culture flasks with 0.05% tryp- 
sin and 0.023% EDTA solution (Boehringer Mannheim, Germany), 
centrifuged and resuspended in culture medium at a concentration f
7.5 x 104 cells/ml. Samples (0.2 ml) were cultured overnight or longer 
in gelatine coated 96-well microtiter plates until confluence was 
reached. Preincubated PBL were added in a final volume of 100/ll 
(1 x 105 cells/well) to the confluent EC-monolayer in 96 microtiter 
plates. At this stage the cells were stimulated with P(Bu)z (100 ng/ml 
final concentration). The labeled and stimulated cells were allowed to 
settle and adhere for 60 min at 37°C and 5% CO2 in an incubator. 
Non-adherent cells were removed by washing with warm medium and 
the remaining cells were lysed with a lysis buffer (0.01 M Tris, 0.15 M 
NaC1, 1.5 mM MgC1, 0.2% Triton X-100, pH 7.3) for 15 min at room 
temperature. Fluorescence was quantified in a fluorescence spectro- 
photometer (Millipore, USA). Percent adherence was calculated as 
follows (FI = fluorescence intensity): 
% adherence = FI adherent - F1 (background) × 100 
FI initial cell number - F1 (background) 
Under the experimental conditions used, about 1 × 105 labeled PBL 
gave a fluorescence intensity of about FI = 3,000-5,000. 
2.6. Flow cytometry 
Isolated PBL were incubated with fluorescein-conjugated monoclo- 
nal antibody (Leu-44 antibody from Becton Dickinson) for direct im- 
munofluorescence, or with unconjugated murine mAB (anti-CDlla, 
clone 25.3.1, from Dianova, anti-CD44, clone J 173, from Dianova) and 
a FITC-conjugated rabbit anti-mouse IgG as secondary antibody for 
indirect immunofluorescence. The different probes were analysed by 
flow cytometry using a FACS scan (Becton Dickinson, Heidelberg, 
Germany). 
2. 7. CD44-neutralisation assay 
About 7.5 × 105 PBL in 100/11 RPMI 1640 were incubated with 5/~g 
of anti-CD44 antibody (Leu-44 antibody, Becton Dickinson) or with 
a CD44 unrelated IgGt antibody for 30 min on ice. F9 was added at 
a final concentration of 50/zg/ml and incubated for 1 h at 370C, 5% 
CO2. F9 treated cells were labeled with BCECF-AM as described 
above. Following washing to remove the fluorescent dye, the adhesion 
assay was performed as described above. 
3. Results 
About  16% of unst imulated PBL adhered to the endothelial 
cells, st imulation with P(Bu)2 (100 ng/ml) significantly increased 
the adherence to HUVEC to about 34%. 
3.1. Effects o fF9  on PBL  adhesion to HUVEC 
Bromelain protease F9, a highly purified fraction from the 
crude bromelain protease mixture, was tested for its effects on 
PBL binding to the endothelial cells. Preincubation of PBL with 
different concentrat ions of F9 reduced its adhesion to HUVEC 
in a dose-dependent manner  (Fig. 1). F9 (25/.tg/ml) reduced the 
adherence of unstimulated PBL to about 23%. Higher concen- 
trations up to 75/ lg/ml of F9 showed only a small increase of 
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Fig. 1. Dose-response curve of bromelain protease F9 induced reduc- 
tion of the adhesion of unstimulated (©) or P(Bu)2 (100 ng/ml) stimu- 
lated (e) PBL. Protease F9 was inactivated (rn) unstimulated, ( I)  stim- 
ulated PBL with iodoacetamide asdescribed. Results are expressed as 
the mean percentage of protease F9 induced ecrease of PBL adhesion 
to HUVEC as compared with PBL without protease treatment (100%). 
Values represent the mean + S.E.M. of triplicates. 
reduction, however. P(Bu)2 stimulated PBL were slightly more 
sensitive to the F9 induced reduction of adherence of the lym- 
phocytes to endothelial cells than unstimulated PBL. At  75 
/.tg/ml of F9, a reduction of 30% PBL-binding was measured. 
However, iodoacetamide inactivated F9 was not effective in 
reducing PBL-binding. At  the highest protease F9 concentra- 
t ion (75/gg/ml) P(Bu)2 stimulated PBL showed only a slight 
reduction in adherence to about 10%, possibly due to a persist- 
ing proteolytic activity at this high protease concentration. 
3.2. Flow cytometry o f  CD44 and CDl la  expression on PBL  
after protease treatment 
Since the adhesion molecules CD44 and LFA-1 (CD1 la) are 
involved in the binding of PBL to HUVEC [9], we analysed the 
effect o fF9  on CD44 and CD1 la expression by flow cytometry. 
Receptor expression was monitored by the respective receptor 
specific ant ibody and a F ITC labeled rabbit  anti-mouse IgG as 
secondary antibody. In the absence of F9 about 37% CD44 
positive and 63% CD1 la positive PBL were measured, respec- 
tively (Fig. 2). F9 at a concentrat ion of 50 ~tg/ml reduced the 
CD44 expression to about 3%. In contrast CD1 la expression 
remained essentialy unchanged and was reduced only slightly 
to a value of 55%. 
Dose-response studies of F9 induced reduction of CD44 
expression revealed, that F9 was active at 2.5/ lg/ml at least. 
From this concentrat ion up to 25/lg/ml,  no CD44 expression 
was detected (Fig. 3). For comparison, the crude bromelain 
extract was significantly less active at 2.5/lg/ml: only 4% reduc- 
tion of CD44 expression was monitored. 
3.3. Monoclonal antibody CD44 effects on PBL  adhesion to 
HUVEC 
Next we tested whether an antibody against CD44 was effec- 
tive in blocking F9 mediated reduction of CD44 expression 
(Fig. 4). First, CD44 antibody was tested for blocking the 
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Fig. 2. Effects of bromelain protease F9 on CD44 and CDI la (LFA-1) expression on PBL. Untreated or protease F9 (10/.tg/ml) treated PBL were 
labeled by indirect immunofluorescence with anti-CD44 antibody (clone J173, from Dianova, Germany) or anti-CD11 aantibody (clone 25.3.1, from 
Dianova, Germany). The expression of the adhesion molecules was monitored using a rabbit anti-mouse-lgG-FITC as secondary antibody. Samples 
were subsequently analyzed by flow cytometry. Values represent the mean + S.E.M. of two replicates. Similar esults were obtained by two other 
experiments. 
PBL-adhesion to endothelial cells in comparison with a CD44 
unrelated IgG~ antibody. Anti-CD44 antibodies reduced the 
PBL-binding to about 24%, the IgG~ control antibodies to 
about 10%. Interestingly, in the same experiment F9, at the 
optimal concentration of 50/lg/ml, reduced the binding of the 
PBL to the same value of 24%, as measured by the anti-CD44 
antibody. 
Incubation of the PBL with anti-CD44 antibodies blocked 
the proteolytic activity of F9, however not to the extent as by 
anti-CD44 antibody alone. In contrast, non-specific IgGl anti- 
body had no blocking activity towards F9. Under these condi- 
tions, about 40% of reduced adherence of PBL to the endothe- 
lial cells was estimated, which is somewhat higher than the 
effect by F9 alone. 
4. Discussion 
The results of the present paper demonstrate, that the bro- 
melain protease F9 reduces the binding of unstimulated and 
P(Bu)2 stimulated PBL to HUVEC, The involvement of CD44 
molecules in the binding process was derived from the following 
lines of evidence: first, using flow cytometry bromelain protease 
F9 reduced the CD44 expression on PBL, without changing 
LFA-1 expression. Second, a mAb CD44 blocked the adhesion 
of PBL to the HUVEC to a similar extent as the bromelain 
protease F9. 
CD44 surface molecules are mainly involved in the binding 
of PBL to mucosal and synovial lymph nodes and but much less 
to peripheral lymph node cells [10]. CD44 has also been shown 
to play a role in binding of activated T-cells to IL-1 stimulated 
endothelial cells [4]. However, measuring the binding of PBL 
to HUVEC we demonstrated, that only 16% of unstimulated 
lymphocytes bound to the endothelial cells. P(Bu)2 stimulation 
of the PBL resulted in an increase to 34% binding. The leuko- 
cyte function associated Ag-I (LFA-1) was reported to play an 
important role in adhesion (60-90% of total adhesion) to endo- 
thelial cells and to be involved in the adhesion of unstimulated 
and P(Bu)2 stimulated T-cells to unstimulated ndothelium [11]. 
Testing the effects of F9 on PBL-binding to HUVEC, only 
about 20% of unstimulated and 30% of P(Bu)2 stimulated lym- 
phocyte adhesion were found to be protease sensitive. There- 
fore, this measured ifference of about 10% in reduction of 
PBL-binding, was somewhat less than the observed P(Bu)2 in- 
duced PBL adhesion (about 15%), suggesting that some ex- 
pressed surface molecules were protease insensitive. 
Using flow cytometry0 F9 reduced the expression of CD44 
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Fig. 3. Flow cytometric analysis of the effects of crude bromelain (&) 
or protease F9 (e) on CD44 expression. PBL were incubated with 
different protease concentrations for 60 min and labeled with Leu-44 
antibody as described. Values represent the mean + S.E.M. of two 
replicates. 
218 
5o 
O 
tlJ 
e- 40 
0 
e- 
0 
M Q 
e- 30 
m 
.J en 
a.  
~- 20 0 
t- 
o 
• o 10 
ant i -CD44 IgG l  F9  ant i -CD44 IgG l  
+ F9  + F9  
Fig. 4. Effect of anti-CD44 antibody on the bromelain protease F9 
induced reduction of PBL adhesion to HUVEC. Anti-Leu-44 and un- 
specific mAb were applied at 5/lg/ml in the absence or presence of 
protease F9 at 50/lg/ml. For details ee section 2. Data are expressed 
as the mean percentage of reduction of PBL adhesion compared with 
PBL adhesion in the absence of any addition. Values represent the 
mean + S.E.M. of 4 independent experiments. 
molecules on PBL to about 97% leaving LFA-1 expression 
essentialy unaltered, suggesting an involvement of CD44 mole- 
cules in PBL-binding to HUVEC. 
Further evidence for the involvement of CD44 came from 
studies using a neutralising CD44 antibody (Leu-44 antibody). 
Saturable monoclonal anti-CD44 antibody concentration i - 
hibited the adhesion of unstimulated PBL to the same extent 
at optimal F9 concentrations (50 pg/ml). In addition, CD44 
antibody was able to block the effect of protease F9, compara- 
ble to PBL-binding of control cells treated with medium alone. 
Therefore, we suggest that F9 affected the binding of the CD44 
antibody to the lymphocytes, possible by a protease induced 
structural modification of the antibody. 
The mechanism of proteolytic action of optimal concentra- 
tion (50/.tg/ml) of F9 on CD44 remains unclear. However, 
investigating the effects of high concentrations of crude bro- 
melain (1 mg/ml) on different T-cell functions, cleavage of the 
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CD44 molecule close to the cell membrane lipid bilayer was 
demonstrated using Western-blot experiments with a polyclo- 
nal CD44 antibody [7]. As pointed out, crude bromelain at high 
concentrations markedly enhanced T-cell activation and in- 
duced T-cell monocyte adhesion in response to CD2 mitogenic 
antibody [7]. It was suggested that CD44 molecules on T-cells 
have a physiological nti-adhesive effect during macrophage-T- 
cell interaction, as shown by enhanced binding of T-cells in the 
presence of mAb against CD44 [12]. However, CD44 on lym- 
phocytes eem to have different adhesion and functional prop- 
erties against different arget cell types. 
Comparing the proteolytic activity of F9 in contrast to crude 
bromelain, purified bromelain F9 was about 15 times more 
active against a synthetic peptide substrate (T. Harrach et al., 
submitted for publication). On the other hand, crude bromelain 
was significantly less active (about 10 times) in reducing CD44 
expression, compared to the purified F9. Therefore, the activity 
of the protease inversely correlated with the number of CD44 
molecule left and CD44 function in the process of PBL-binding 
to HUVEC. Whether other F9 sensitive surface molecules on 
PBL, besides CD44, were also involved in this process, remains 
to be demonstrated. 
Finally, in view of these results and the proposed antimeta- 
static potential of bromelain [13], further studies on bromelain 
effects on CD44 and CD44-splice variant expression on meta- 
static tumor cells are warranted. 
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